MALARIA AND OTHER PARASITIC DISEASES
|
Assay
|
Model system
|
Disease area
|
Sample quantity required
|
Tentative time required for assay
|
Plasmodium falciparum
SYBR Green based assay |
In- vitro: whole cell assay |
Malaria |
10 mg
|
1 month |
| Plasmodium berghei GFP based assay |
In vitro hepatocyte development assay |
Malaria |
50 mg |
3 month |
|
Plasmodium yoelii ( N-67) - Swiss mice
|
In-vivo: Primary model for tissue Schizontocidal assay
|
Malaria |
100 mg |
3 month |
| Plasmodium berghei C57BL/6 mice
|
In-vivo malaria liver stage development inhibition assay
|
Malaria |
200 mg |
3 month |
|
Plasmodium yoelii ( N-67))/ Plasmodium yoelii MDR/Swiss mice
|
In-vivo blood Schizontocidal assay
|
Malaria |
100 mg |
2 month |
|
Plasmodium cynomolgi - Rhesus monkey |
In-vivo: Secondary model for blood Schizontocidal / Anti-relapse assay |
Malaria |
2 gm |
6 month |
|
Leishmania donovani -Macrophase- Amastigote Luciferase based assay |
In vitro: whole cell assay |
Leishmaniasis |
3.0 gm |
1 month |
|
Leishmania donovani- Macrophase- Amastigote GFP based assay
|
In vitro: whole cell assay |
Leishmaniasis |
15 mg
|
1 month |
|
Leishmania donovani Golden hamster chronic model |
In vivo: assay |
Leishmaniasis |
300 mg
|
2 months |
|
Brugia malayi- MTT and motility assay |
In vitro: whole parasite assay |
Filariasis |
10 mg |
1 month |
| Brugia malayi- Adult transplanted in JIRD |
In vivo: Primary assay |
Filariasis |
150 mg |
2 months |
| L3 induced Brugia malayi- Mastomys
|
In vivo: Secondary model |
Filariasis |
250 mg |
9 months |
* Minimum Quantity of the compound required, running cost of the assay and time required for the assay shall be communicated on request